Provenge is a $93,000 drug that has been shown to extend the lives of some advanced prostate cancer patients by an average of 4.1 months, to 25.8 months.
Each course is three infusions. We can then assume that each month of life in a person with advanced prostate cancer is valued around $23,000.
The government is deciding this week whether or not Medicare will pay for this drug.
You must be logged in to post a comment.